EP Patent

EP2865385A1 — Uses of aromatic-cationic peptide

Assigned to Institut de Recherches Cliniques de Montreal IRCM · Expires 2015-04-29 · 11y expired

What this patent protects

The present invention relates to the use of a specific aromatic-cationic peptide to enhance the preservation of a removed organ.

USPTO Abstract

The present invention relates to the use of a specific aromatic-cationic peptide to enhance the preservation of a removed organ.

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2865385A1
Jurisdiction: EP
Classification: —
Expires: 2015-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Institut de Recherches Cliniques de Montreal IRCM
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.